Global Tuberculosis Therapeutics 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR062414380

Publication Date:

June 26, 2024

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Tuberculosis Therapeutics market size was valued at USD 864.4 million in 2023 and is forecast to a readjusted size of USD 1047 million by 2030 with a CAGR of 2.8% during review period.
Tuberculosis听(TB) is an infectious disease usually caused by Mycobacterium听tuberculosis听(MTB) bacteria.听Tuberculosis听generally affects the lungs, but can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent听tuberculosis.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report includes an overview of the development of the Tuberculosis Therapeutics industry chain, the market status of Hospital (Isoniazid, Rifampin), Pharmacy (Isoniazid, Rifampin), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Tuberculosis Therapeutics.
Regionally, the report analyzes the Tuberculosis Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Tuberculosis Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Tuberculosis Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Tuberculosis Therapeutics industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Isoniazid, Rifampin).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Tuberculosis Therapeutics market.
Regional Analysis: The report involves examining the Tuberculosis Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Tuberculosis Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Tuberculosis Therapeutics:
Company Analysis: Report covers individual Tuberculosis Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Tuberculosis Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Pharmacy).
Technology Analysis: Report covers specific technologies relevant to Tuberculosis Therapeutics. It assesses the current state, advancements, and potential future developments in Tuberculosis Therapeutics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Tuberculosis Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Tuberculosis Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Isoniazid
Rifampin
Pyrazinamide
Hydrazine Derivatives
Miscellaneous Anti-Tubercular Drugs
Ethambutol
Others
麻豆原创 segment by Application
Hospital
Pharmacy
Clinics
Others
麻豆原创 segment by players, this report covers
Aventis Pharmaceuticals
Sanofi -Aventis
Versapharma Incorporated
Sigma Pharmaceutical Pty
Novartis AG
Hoffmann-La Roche
Bayer Health Care
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Tuberculosis Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Tuberculosis Therapeutics, with revenue, gross margin and global market share of Tuberculosis Therapeutics from 2019 to 2024.
Chapter 3, the Tuberculosis Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Tuberculosis Therapeutics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Tuberculosis Therapeutics.
Chapter 13, to describe Tuberculosis Therapeutics research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope of Tuberculosis Therapeutics
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Tuberculosis Therapeutics by Type
1.3.1 Overview: Global Tuberculosis Therapeutics 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Tuberculosis Therapeutics Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Isoniazid
1.3.4 Rifampin
1.3.5 Pyrazinamide
1.3.6 Hydrazine Derivatives
1.3.7 Miscellaneous Anti-Tubercular Drugs
1.3.8 Ethambutol
1.3.9 Others
1.4 Global Tuberculosis Therapeutics 麻豆原创 by Application
1.4.1 Overview: Global Tuberculosis Therapeutics 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Pharmacy
1.4.4 Clinics
1.4.5 Others
1.5 Global Tuberculosis Therapeutics 麻豆原创 Size & Forecast
1.6 Global Tuberculosis Therapeutics 麻豆原创 Size and Forecast by Region
1.6.1 Global Tuberculosis Therapeutics 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Tuberculosis Therapeutics 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Tuberculosis Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Tuberculosis Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Tuberculosis Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Tuberculosis Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Tuberculosis Therapeutics 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Aventis Pharmaceuticals
2.1.1 Aventis Pharmaceuticals Details
2.1.2 Aventis Pharmaceuticals Major Business
2.1.3 Aventis Pharmaceuticals Tuberculosis Therapeutics Product and Solutions
2.1.4 Aventis Pharmaceuticals Tuberculosis Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Aventis Pharmaceuticals Recent Developments and Future Plans
2.2 Sanofi -Aventis
2.2.1 Sanofi -Aventis Details
2.2.2 Sanofi -Aventis Major Business
2.2.3 Sanofi -Aventis Tuberculosis Therapeutics Product and Solutions
2.2.4 Sanofi -Aventis Tuberculosis Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Sanofi -Aventis Recent Developments and Future Plans
2.3 Versapharma Incorporated
2.3.1 Versapharma Incorporated Details
2.3.2 Versapharma Incorporated Major Business
2.3.3 Versapharma Incorporated Tuberculosis Therapeutics Product and Solutions
2.3.4 Versapharma Incorporated Tuberculosis Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Versapharma Incorporated Recent Developments and Future Plans
2.4 Sigma Pharmaceutical Pty
2.4.1 Sigma Pharmaceutical Pty Details
2.4.2 Sigma Pharmaceutical Pty Major Business
2.4.3 Sigma Pharmaceutical Pty Tuberculosis Therapeutics Product and Solutions
2.4.4 Sigma Pharmaceutical Pty Tuberculosis Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Sigma Pharmaceutical Pty Recent Developments and Future Plans
2.5 Novartis AG
2.5.1 Novartis AG Details
2.5.2 Novartis AG Major Business
2.5.3 Novartis AG Tuberculosis Therapeutics Product and Solutions
2.5.4 Novartis AG Tuberculosis Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Novartis AG Recent Developments and Future Plans
2.6 Hoffmann-La Roche
2.6.1 Hoffmann-La Roche Details
2.6.2 Hoffmann-La Roche Major Business
2.6.3 Hoffmann-La Roche Tuberculosis Therapeutics Product and Solutions
2.6.4 Hoffmann-La Roche Tuberculosis Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Hoffmann-La Roche Recent Developments and Future Plans
2.7 Bayer Health Care
2.7.1 Bayer Health Care Details
2.7.2 Bayer Health Care Major Business
2.7.3 Bayer Health Care Tuberculosis Therapeutics Product and Solutions
2.7.4 Bayer Health Care Tuberculosis Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Bayer Health Care Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Tuberculosis Therapeutics Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Tuberculosis Therapeutics by Company Revenue
3.2.2 Top 3 Tuberculosis Therapeutics Players 麻豆原创 Share in 2023
3.2.3 Top 6 Tuberculosis Therapeutics Players 麻豆原创 Share in 2023
3.3 Tuberculosis Therapeutics 麻豆原创: Overall Company Footprint Analysis
3.3.1 Tuberculosis Therapeutics 麻豆原创: Region Footprint
3.3.2 Tuberculosis Therapeutics 麻豆原创: Company Product Type Footprint
3.3.3 Tuberculosis Therapeutics 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Tuberculosis Therapeutics Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Tuberculosis Therapeutics 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Tuberculosis Therapeutics Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Tuberculosis Therapeutics 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Tuberculosis Therapeutics Consumption Value by Type (2019-2030)
6.2 North America Tuberculosis Therapeutics Consumption Value by Application (2019-2030)
6.3 North America Tuberculosis Therapeutics 麻豆原创 Size by Country
6.3.1 North America Tuberculosis Therapeutics Consumption Value by Country (2019-2030)
6.3.2 United States Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Tuberculosis Therapeutics Consumption Value by Type (2019-2030)
7.2 Europe Tuberculosis Therapeutics Consumption Value by Application (2019-2030)
7.3 Europe Tuberculosis Therapeutics 麻豆原创 Size by Country
7.3.1 Europe Tuberculosis Therapeutics Consumption Value by Country (2019-2030)
7.3.2 Germany Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Tuberculosis Therapeutics Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Tuberculosis Therapeutics Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Tuberculosis Therapeutics 麻豆原创 Size by Region
8.3.1 Asia-Pacific Tuberculosis Therapeutics Consumption Value by Region (2019-2030)
8.3.2 China Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Tuberculosis Therapeutics Consumption Value by Type (2019-2030)
9.2 South America Tuberculosis Therapeutics Consumption Value by Application (2019-2030)
9.3 South America Tuberculosis Therapeutics 麻豆原创 Size by Country
9.3.1 South America Tuberculosis Therapeutics Consumption Value by Country (2019-2030)
9.3.2 Brazil Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Tuberculosis Therapeutics Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Tuberculosis Therapeutics Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Tuberculosis Therapeutics 麻豆原创 Size by Country
10.3.1 Middle East & Africa Tuberculosis Therapeutics Consumption Value by Country (2019-2030)
10.3.2 Turkey Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Tuberculosis Therapeutics 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Tuberculosis Therapeutics 麻豆原创 Drivers
11.2 Tuberculosis Therapeutics 麻豆原创 Restraints
11.3 Tuberculosis Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Tuberculosis Therapeutics Industry Chain
12.2 Tuberculosis Therapeutics Upstream Analysis
12.3 Tuberculosis Therapeutics Midstream Analysis
12.4 Tuberculosis Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Aventis Pharmaceuticals
Sanofi -Aventis
Versapharma Incorporated
Sigma Pharmaceutical Pty
Novartis AG
Hoffmann-La Roche
Bayer Health Care

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.